Adaptive Biotechnologies Corp (NASDAQ:ADPT) has a beta value of 1.93 and has seen 1.59 million shares traded in the last trading session. The company, currently valued at $1.68B, closed the last trade at $11.06 per share which meant it lost -$0.49 on the day or -4.24% during that session. The ADPT stock price is -12.39% off its 52-week high price of $12.43 and 65.19% above the 52-week low of $3.85. If we look at the company’s 10-day average daily trading volume, we find that it stood at 1.89 million shares traded. The 3-month trading volume is 2.16 million shares.
The consensus among analysts is that Adaptive Biotechnologies Corp (ADPT) is Hold stock at the moment, with a recommendation rating of 1.25. 1 analysts rate the stock as a Sell, while 0 rate it as Overweight. 6 out of 11 have rated it as a Hold, with 4 advising it as a Buy. 0 have rated the stock as Underweight. The expected earnings per share for the stock is -0.24.
Adaptive Biotechnologies Corp (NASDAQ:ADPT) trade information
Sporting -4.24% in the red in last session, the stock has traded in the red over the last five days, with the highest price hit on recent trading when the ADPT stock price touched $11.06 or saw a rise of 10.45%. Year-to-date, Adaptive Biotechnologies Corp shares have moved 184.32%, while the 5-day performance has seen it change -5.79%. Over the past 30 days, the shares of Adaptive Biotechnologies Corp (NASDAQ:ADPT) have changed 6.24%. Short interest in the company has seen 8.93 million shares shorted with days to cover at 7.32.
Wall Street analysts have a consensus price target for the stock at $14, which means that the shares’ value could jump 21.0% from current levels. The projected low price target is $5.0 while the price target rests at a high of $18.0. In that case, then, we find that the current price level is -62.75% off the targeted high while a plunge would see the stock lose 54.79% from current levels.
Adaptive Biotechnologies Corp (ADPT) estimates and forecasts
The company’s shares have gained 70.15% over the past 6 months. Revenue growth from the last financial year stood is estimated to be 21.96%.
7 analysts offering their estimates for the company have set an average revenue estimate of 49.4M for the current quarter. 7 have an estimated revenue figure of 55.18M for the next ending quarter. Year-ago sales stood 43.19M and 46.44M respectively for this quarter and the next, and analysts expect sales will grow by 14.37% for the current quarter and 21.96% for the next.
If we evaluate the company’s growth over the last 5-year and for the next 5-year period, we find that annual earnings growth was -1.51% over the past 5 years. Earnings growth for 2025 is a modest 21.47% while over the next 5 years, the company’s earnings are expected to increase by 30.19%.
ADPT Dividends
Adaptive Biotechnologies Corp is expected to release its next earnings report on 2025-May-01 this year, and investors are excited at the prospect of better dividends despite the company’s debt issue.
Adaptive Biotechnologies Corp (NASDAQ:ADPT)’s Major holders
Insiders own 2.35% of the company shares, while shares held by institutions stand at 98.36% with a share float percentage of 100.72%. Investors are also buoyed by the number of investors in a company, with Adaptive Biotechnologies Corp having a total of 311.0 institutions that hold shares in the company. The top two institutional holders are VIKING GLOBAL INVESTORS LP with over 29.99 million shares worth more than $108.58 million. As of 2024-06-30, VIKING GLOBAL INVESTORS LP held 20.3466% of shares outstanding.
The other major institutional holder is RUBRIC CAPITAL MANAGEMENT LP, with the holding of over 14.0 million shares as of 2024-06-30. The firm’s total holdings are worth over $50.68 million and represent 9.4971% of shares outstanding.
